Compare

Evotec SE/€EVT

1D1W1M3M6MYTD1Y5YMAX

About Evotec SE

Evotec SE is a biotechnology company specializing in drug discovery and development solutions across various therapeutic areas, including neuroscience, oncology, and metabolic diseases. The company provides integrated services and innovative research through its platforms, such as EVOequity and INDiGO, which accelerate drug candidates from discovery to commercialization. Founded in 1993, Evotec is headquartered in Hamburg, Germany, and operates worldwide with multiple research sites in Europe and the United States. Through strategic collaborations with pharmaceutical and academic institutions, Evotec enhances its research capabilities and expands its global reach, leveraging advanced technologies and a collaborative approach to drive innovation in drug development.
Ticker
€EVT
Sector
Health
Primary listing
XETRA
Employees
4,461
Headquarters
Hamburg, Germany
Website
www.evotec.com

Evotec SE Metrics

BasicAdvanced
€501M
-
-€1.11
1.26
-

What the Analysts think about Evotec SE

Analyst ratings (Buy, Hold, Sell) for Evotec SE stock.
Analyst projections of the future price of Evotec SE stock.

Bulls say / Bears say

Preliminary nine-month revenue of about €465m and an adjusted EBITDA loss of €42.8m came in above market expectations, and Evotec reaffirmed its full-year outlook. The company said the beat largely reflected the timing of consensus estimates, so it suggests stability rather than a clear turnaround. (EQS News)
H1 net sales in Drug Discovery & Preclinical Development, excluding strategic partnerships, rose 28% year on year; Just – Evotec Biologics also reported high capacity use and a wider customer base. These signs point to firmer activity in parts of the core business, despite lower group revenue. (Evotec)
Just – Evotec Biologics advanced its orthopoxvirus antibody programme into Phase 1, delivering a key development milestone under a US Department of War contract. The two announced antibody-programme contracts have potential value of up to $123.9m combined. (Evotec)
Evotec cut its 2026 revenue outlook to €570–610m from €700–780m and moved its adjusted EBITDA outlook from a possible profit to a €70–105m loss. Delayed milestones and slower-than-expected new partnership activity are weighing on the near-term outlook. (Evotec)
H1 group revenue fell 19.2% year on year to €300.1m, adjusted EBITDA swung to a €42.7m loss and the reported net loss widened to €168.6m. The weak results show how far the business remains from profitable growth. (Evotec)
Operating cash flow was negative €111.1m in H1, while net debt reached €127.5m and Evotec issued €116.1m in convertible bonds. Continued cash use increases financing risk, and conversion of the bonds could dilute shareholders. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.

Evotec SE Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Evotec SE Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Evotec SE

AllEURUSDGBP
Funds
Fund name
Fund size
€EVT weighting
iShares TecDAX€EXS2
€645M0.36%
iShares Healthcare Innovation£DRDR
$1.3B0.05%
iShares Healthcare Innovation€2B78
$1.2B0.05%
iShares Healthcare Innovation$HEAL
$1.3B0.05%
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.03%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.